Study on the interaction of triaryl-dihydro-1,2,4-oxadiazoles with α-glucosidase

  • Arefeh Khosravi
  • Gholamhassan VaeziEmail author
  • Vida Hojati
  • Khosrou AbdiEmail author
Research article



One of the therapeutic approaches in the management of Type 2 diabetes is delaying the absorption of glucose through α-glucosidase enzymes inhibition, which can reduce the incidence of postprandial hyperglycemia. The existence of chronic postprandial hyperglycemia impaired the endogenous antioxidant defense due to inducing oxidative stress induced pancreatic β-cell destruction through uncontrolled free radicals generation such as ROS, which in turn, leads to various macrovascular and microvascular complications. This study aimed to synthesize 2-aryl-4,6-diarylpyrimidine derivatives, screen their α-glucosidase inhibitory activity, perform kinetic and molecular docking studies.


A series of 3,4,5-triphenyl-4,5-dihydro-1,2,4-oxadiazole derivatives were synthesized and their α-glucosidase inhibitory activity was screened in vitro. Compounds 6a-k were synthesized via a two-step reaction with a yield between 65 and 88%. The structural elucidation of the synthesized derivatives was performed by different spectroscopic techniques. α-Glucosidase inhibitory activity of the oxadiazole derivatives 6a-k was evaluated against Saccharomyces cerevisiae α-glucosidase.


Most of the synthesized compounds demonstrated α-glucosidase inhibitory action. Particularly compounds 6c, 6d and 6 k were the most active compounds with IC50 values 215 ± 3, 256 ± 3, and 295 ± 4 μM respectively. A kinetic study performed for compound 6c revealed that the compound is a competitive inhibitor of Saccharomyces cerevisiae α-glucosidase with Ki of 122 μM. The docking study also revealed that the two compounds, 6c and 6 k, have important binding interactions with the enzyme active site.


The overall results of our study reveal that the synthesized compounds could be a potential candidate in the search for novel α-glucosidase inhibitors to manage the postprandial hyperglycemia incidence.

Graphical abstract


1,2,4-oxadiazoles α-Glucosidase activity Docking Kinetic study 



The authors would like to express their thankfulness to Tehran University of Medical Sciences for providing the research data facilities.

Compliance with ethical standards

Conflict of interest

The authors declare no conflict of interest.

Supplementary material

40199_2019_322_MOESM1_ESM.pdf (2.8 mb)
ESM 1 (PDF 2861 kb)


  1. 1.
    Barcelo A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the Americas. Rev Panam Salud Publica. 2001;10:300–8.CrossRefGoogle Scholar
  2. 2.
    Shojaii A, Dabaghian FH, Goushegir A, Fard MA. Antidiabetic plants of Iran. Acta Med Iran. 2011;49:637–42.PubMedGoogle Scholar
  3. 3.
    Tafesse TB, Hymete A, Mekonnen Y, Tadesse M. Antidiabetic activity and phytochemical screening of extracts of the leaves of Ajuga remota Benth on alloxan-induced diabetic mice. BMC Complement Altern Med. 2017;17:243.CrossRefGoogle Scholar
  4. 4.
    Rao M. Phytochemical screening and In Vitro antioxidant and anti-diabetic potentials of Persea Americana Mill. (Lauraceae) fruit extract. Universal J Pharm Res. 2018;3:38–45.CrossRefGoogle Scholar
  5. 5.
    Maki KC, Carson ML, Miller MP, Turowski M, Bell M, Wilder DM, et al. High-viscosity hyrdoxypropylmethylcellulose blunts postprandial glucose and insulin responses. Diabetes Care. 2007;30:1039–43.CrossRefGoogle Scholar
  6. 6.
    Ibrahim MA, Koorbanally NA, Islam MS. Antioxidative activity and inhibition of key enzymes linked to type-2 diabetes (α-glucosidase and α-amylase) by Khaya senegalensis. Acta Pharma. 2014;64:311–24.CrossRefGoogle Scholar
  7. 7.
    Rouzbehan S, Moein S, Homaei A, Moein MR. Kinetics of α-glucosidase inhibition by different fractions of three species of Labiatae extracts: a new diabetes treatment model. Pharm Biol. 2017;55:1483–8.CrossRefGoogle Scholar
  8. 8.
    Mccue P, Kwon YI, Shetty K. Anti-amylase, anti-glucosidase and anti-angiotensin I converting enzyme potential of selected foods. J Food Biochem. 2005;29:278–94.CrossRefGoogle Scholar
  9. 9.
    Rubin R, Strayer DS, Rubin E. Rubin's pathology: Clinicopathologic foundations of medicine. 6rd ed. Philadelphia: Lippincott Williams & Wilkins; 2012.Google Scholar
  10. 10.
    Kim KY, Nam KA, Kurihara H, Kim SM. Potent α-glucosidase inhibitors purified from the red alga Grateloupia elliptica. Phytochemistry. 2008;69(16):2820–5.CrossRefGoogle Scholar
  11. 11.
    Bischoff H. Pharmacology of alpha-glucosidase inhibition. Eur J Clin Investig. 1994;24:3–10.CrossRefGoogle Scholar
  12. 12.
    Bruni CB, Sica V, Auricchio F, Covelli I. Further kinetic and structural characterization of the lysosomal α-D-glucoside glucohydrolase from cattle liver. Biochim Biophys Acta. 1990;212:470–7.CrossRefGoogle Scholar
  13. 13.
    Saeedi M, Mohammadi-Khanaposhtani M, Pourrabia P, Razzaghi N, Ghadimi R, Imanparast S, et al. Design and synthesis of novel quinazolinone-1,2,3-triazole hybrids as new anti-diabetic agents: in vitro α-glucosidase inhibition, kinetic, and docking study. Bioorg Chem. 2019;83:161–9.CrossRefGoogle Scholar
  14. 14.
    Yin Z, Zhang W, Feng F, Zhang Y, Kang W. α-Glucosidase inhibitors isolated from medicinal plants. Food Sci Human Wellness. 2014;3:136–74.CrossRefGoogle Scholar
  15. 15.
    Wang G, Li X, Wang J, Xie Z, Li L, Chen M, et al. Synthesis, molecular docking and α- glucosidase inhibition of 2-((5,6-diphenyl-1,2,4-triazin-3-yl)thio)-N-arylacetamides. Bioorg Med Chem Lett. 2017;27:1115–8.CrossRefGoogle Scholar
  16. 16.
    Wang G, Peng Z, Wang J, Li J, Li X. Synthesis and biological evaluation of novel 2,4,5-triarylimidazole– 1,2,3-triazole derivatives via click chemistry as a-glucosidase inhibitors. Bioorg Med Chem Lett. 2016;26:5719–23.CrossRefGoogle Scholar
  17. 17.
    Goel A, Agarwal N, Singh FV, Sharon A, Tiwari P, Dixit M, et al. Antihyperglycemic activity of 2-methyl-3,4,5-triaryl-1H-pyrroles in SLM and STZ models. Bioorg Med Chem Lett. 2004;14:1089–92.CrossRefGoogle Scholar
  18. 18.
    Alcaide B, Mardomingo CL, Plumet J, Cativiela C, Mayoral A. Orbital control in the 1,3-dipolar cycloaddition of benzonitrile oxide to benzylideneanilines. Can J Chem. 1987;65:2050–6.CrossRefGoogle Scholar
  19. 19.
    Guerreiro LR, Carreiro EP, Fernandes L, Cardote TA, Moreira R, Caldeira AT, et al. Five-membered iminocyclitol α-glucosidase inhibitors: synthetic, biological screening and in silico studies. Bioorg Med Chem. 2013;21:1911–7.CrossRefGoogle Scholar
  20. 20.
    Hati S, Madurkar SM, Bathula C, Thulluri C, Agarwal R, Siddiqui FA, et al, Synthesis and biological evaluation of small molecules as potent glucosidase inhibitors. Eur J Med Chem 2015;100:188–196.Google Scholar
  21. 21.
    Liu KC, Shelton BR, Howe RK. A particularly convenient preparation of bezohydroximinoyl chlorides (nitrile oxide precursors). J Org Chem. 1980;45:3916–8.CrossRefGoogle Scholar
  22. 22.
    Miralinaghi P, Norouzi M, Shafiee A, Salimi M, Amirhamzeh A, Kandelousi HM, et al. Synthesis, molecular docking study, and anticancer activity of triaryl-1,2,4-oxadiazole. Med Chem Res. 2013;22:4253–63.CrossRefGoogle Scholar
  23. 23.
    Nikookar H, Mohammadi-Khanaposhtani M, Imanparast S, Faramarzi MA, Ranjbar PR, Mahdavi M, et al. Design, synthesis and in vitro α-glucosidase inhibition of novel dihydropyrano[3,2-c]quinoline derivatives as potential anti-diabetic agents. Bioorg Chem. 2018;77:280–6.CrossRefGoogle Scholar
  24. 24.
    Wang G, Peng Z, Wang J, Li X, Li J. Synthesis, in vitro evaluation and molecular docking studies of novel triazine-triazole derivatives as potential a-glucosidase inhibitors. Eur J Med Chem. 2017;125:423–9.CrossRefGoogle Scholar
  25. 25.
    Wang G, Wang J, He D, Li X, Li J, Peng Z. Synthesis and biological evaluation of novel 1,2,4-triazine derivatives bearing carbazole moiety as potent a-glucosidase inhibitors. Bioorg Med Chem Lett. 2016;26:2806–9.CrossRefGoogle Scholar
  26. 26.
    Chiba S, Shimomura T. Diversity of substrate specificity of α-glucosidase. J JPN Soc Starch Sci. 1978;25:105–12.CrossRefGoogle Scholar
  27. 27.
    Ghasemi Y, Mehraban MH. A computational comparative study of α-Glucosidase enzyme divergence. J Appl Bioinform Comput Biol. 2015;4:1–5.Google Scholar
  28. 28.
    Kang WY, Song Y, Zhang L. α-Glucosidase inhibitory, antioxidant properties and antidiabetic activity of Hypericum ascyron L. Med Chem Res. 2011;20:809–16.CrossRefGoogle Scholar
  29. 29.
    Sun H, Ding W, Song X, Wang D, Chen M, Wang K, et al. Synthesis of 6-hydroxyaurone analogues and evaluation of their α-glucosidase inhibitory and glucose consumption-promoting activity: development of highly active 5,6-disubstituted derivatives. Bioorg Med Chem Lett. 2017;27:3226–30.CrossRefGoogle Scholar
  30. 30.
    Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785–91.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of BiologyDamghan branch, Islamic Azad UniversityDamghanIran
  2. 2.Department of ChemistryIslamic Azad University, North Tehran BranchTehranIran
  3. 3.Department of Medicinal Chemistry and RadiopharmacyTehran University of Medical Sciences TehranIran

Personalised recommendations